JP2012504602A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012504602A5 JP2012504602A5 JP2011530033A JP2011530033A JP2012504602A5 JP 2012504602 A5 JP2012504602 A5 JP 2012504602A5 JP 2011530033 A JP2011530033 A JP 2011530033A JP 2011530033 A JP2011530033 A JP 2011530033A JP 2012504602 A5 JP2012504602 A5 JP 2012504602A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- hcv
- epitope
- cell line
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2008/078884 WO2010039154A1 (en) | 2008-10-05 | 2008-10-05 | Hepatitis c antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012504602A JP2012504602A (ja) | 2012-02-23 |
| JP2012504602A5 true JP2012504602A5 (enExample) | 2012-11-01 |
Family
ID=42073762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011530033A Withdrawn JP2012504602A (ja) | 2008-10-05 | 2008-10-05 | Ｃ型肝炎抗体およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8858947B2 (enExample) |
| EP (1) | EP2331573A4 (enExample) |
| JP (1) | JP2012504602A (enExample) |
| KR (1) | KR20110061624A (enExample) |
| CN (1) | CN102197050A (enExample) |
| AU (1) | AU2008362482A1 (enExample) |
| BR (1) | BRPI0823197A2 (enExample) |
| CA (1) | CA2738644A1 (enExample) |
| EA (1) | EA201170353A1 (enExample) |
| IL (1) | IL212040A0 (enExample) |
| MX (1) | MX2011003613A (enExample) |
| WO (1) | WO2010039154A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8592559B2 (en) | 2009-10-30 | 2013-11-26 | Toray Industries, Inc. | Antibody having activity of inhibiting hepatitis C virus (HCV) infection and use thereof |
| WO2012107589A1 (en) * | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
| US9512183B2 (en) | 2011-05-02 | 2016-12-06 | The Johns Hopkins University | Synthetic hepatitis C genome and methods of making and use |
| EP2882453B1 (en) | 2012-08-07 | 2021-01-06 | Massachusetts Institute of Technology | Anti-dengue virus antibodies and uses thereof |
| CN103172705B (zh) * | 2013-02-27 | 2014-08-20 | 北京大学人民医院 | 丙型肝炎病毒b细胞表位肽puhi16及其应用 |
| CN103113458B (zh) * | 2013-02-27 | 2014-08-20 | 北京大学人民医院 | 丙型肝炎病毒b细胞表位肽puhi34及其应用 |
| RU2539770C1 (ru) | 2013-12-27 | 2015-01-27 | Татьяна Николаевна Власик | Способ нейтрализации вируса гепатита с, полностью человеческое моноклональное антитело против вируса гепатита с (варианты), композиция полностью человеческих моноклональных антител против вируса гепатита с и гибридная мышь/человек клеточная линия - продуцент полностью человеческих моноклональных антител против вируса гепатита с (варианты) |
| SG10201807826XA (en) | 2014-02-11 | 2018-10-30 | Massachusetts Inst Technology | Novel full spectrum anti-dengue antibody |
| JPWO2015133467A1 (ja) * | 2014-03-06 | 2017-04-06 | 株式会社シノテスト | Ｃ型肝炎ウイルスのワクチン及び診断に用いるためのＨＢｃ／ＨＣＶ Ｅ２ペプチドキメラタンパク質 |
| CN104327170A (zh) * | 2014-05-16 | 2015-02-04 | 中国疾病预防控制中心病毒病预防控制所 | 丙型肝炎病毒(hcv)细胞进入抑制肽zte1序列及应用 |
| GB201415714D0 (en) * | 2014-09-05 | 2014-10-22 | Medical Res Council | Antibodies and antigen binding fragments thereof |
| CN105254756B (zh) * | 2015-11-27 | 2018-09-07 | 武汉大学 | 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用 |
| KR102640157B1 (ko) * | 2016-03-22 | 2024-02-27 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 인간화 항-클라우딘-1 항체 및 이의 용도 |
| CN107011435B (zh) * | 2016-06-01 | 2019-02-12 | 苏州银河生物医药有限公司 | 抗丙型肝炎病毒的全人单克隆抗体8d6 |
| EP4095156A1 (en) * | 2021-05-28 | 2022-11-30 | Universität zu Köln | Neutralizing antibodies against hepatitis c virus |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7091324B2 (en) * | 1998-11-05 | 2006-08-15 | Board Of Trustees Of Leland Stanford Junior University | Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes |
| WO2000026418A1 (en) * | 1998-11-05 | 2000-05-11 | The Board Of Trustees Of Leland Stanford Junior University | Human pan-hcv human monoclonal antibodies |
| EP1618127B1 (en) * | 2003-04-10 | 2014-12-10 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic composition comprising a spike protein of the SARS coronavirus |
-
2008
- 2008-10-05 EA EA201170353A patent/EA201170353A1/ru unknown
- 2008-10-05 EP EP08824626A patent/EP2331573A4/en not_active Withdrawn
- 2008-10-05 KR KR1020117008883A patent/KR20110061624A/ko not_active Withdrawn
- 2008-10-05 MX MX2011003613A patent/MX2011003613A/es unknown
- 2008-10-05 BR BRPI0823197-4A patent/BRPI0823197A2/pt not_active IP Right Cessation
- 2008-10-05 CA CA2738644A patent/CA2738644A1/en not_active Abandoned
- 2008-10-05 AU AU2008362482A patent/AU2008362482A1/en not_active Abandoned
- 2008-10-05 JP JP2011530033A patent/JP2012504602A/ja not_active Withdrawn
- 2008-10-05 US US13/122,598 patent/US8858947B2/en not_active Expired - Fee Related
- 2008-10-05 WO PCT/US2008/078884 patent/WO2010039154A1/en not_active Ceased
- 2008-10-05 CN CN2008801313970A patent/CN102197050A/zh active Pending
-
2011
- 2011-03-31 IL IL212040A patent/IL212040A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012504602A5 (enExample) | ||
| Xia et al. | Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein | |
| Tsukuda et al. | A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins | |
| WO2006041866A3 (en) | Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes | |
| JP2018135370A (ja) | 感染性疾患を治療及び予防する組み合わせ医薬組成物及び方法 | |
| JP2010100624A5 (enExample) | ||
| JP4287280B2 (ja) | ＨＣＶＥ２グリコプロテインに対して向けられ、ｉｎｖｉｔｒｏ中和活性を有するヒトモノクローナル抗体Ｆａｂ断片 | |
| JP2010501594A5 (enExample) | ||
| JP2017113019A5 (enExample) | ||
| CN114736291B (zh) | 特异性结合发热伴血小板减少综合征病毒的囊膜蛋白Gn的人源单克隆抗体及其用途 | |
| CA3181026A1 (en) | Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies | |
| Wang et al. | A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapy | |
| CN106749644B (zh) | 一种全人源抗hcv的中和抗体-trn1001 | |
| TWI511977B (zh) | 抗登革熱病毒非結構性蛋白１之單株抗體及其用途 | |
| JP2004533991A5 (enExample) | ||
| CN101851274B (zh) | 抑制丙型肝炎病毒侵入的多肽 | |
| JP2011529882A5 (enExample) | ||
| EP1305418B1 (en) | Human monoclonal antibody against hepatitis c virus e2 glycoprotein | |
| CN115850461A (zh) | 沙贝病毒广谱中和抗体及其应用 | |
| JP2006504645A5 (enExample) | ||
| Su et al. | Opportunities and challenges to the use of neutralizing monoclonal antibody therapies for COVID-19 | |
| AU2001282425A1 (en) | Human monoclonal antibody against hepatitis C virus E2 glycoprotein | |
| JP2014012683A5 (enExample) | ||
| Tada et al. | Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex | |
| CN116178530A (zh) | 抗体在治疗SARS-CoV-2感染的用途 |